Gilead Sciences GILD +2.54% Get Free Report has outperformed the market over the past 20 years by 4.74% on an annualized ...

In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gilead Sciences (GILD – Research Report) and ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ ... sustainability reporting requirements, setting a high bar for corporate transparency and responsibility.

Gilead Sciences Inc (GILD) stock saw a decline, ending the day at $92.92 which represents a decrease of $-0.12 or -0.13% from the prior close of $93.04. The stock opened at $93.03 and touched a low of ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $93.07 which represents a slight increase of $0.15 or 0.16% from the prior close of $92.92. The stock opened at $92.36 and ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. Galapagos NV plans to split into two entities ...

The stock's fall snapped a two-day winning streak.

We recently compiled a list of the 8 Best Humane Stocks to Invest in Now. In this article, we are going to take a look at ...

$2,440,000 of GILEAD SCIENCES INC lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "International trade and protection ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This was the stock's second consecutive day of gains.